Generic Drugs Market Forecast 2017-2027

1. Report Overview
1.1 Global Generic Drugs: Market Overview
1.2 Global Generic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is this Report for?
1.7 Methodology
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. An Introduction to Generic Drugs
2.1 An Introduction to the Rise of Generic Drugs
2.2 What Are Generic Drugs?
2.2.1 Generic Active Ingredients
2.3 A Brief Overview of the Pharmaceutical Industry
2.3.1 Brief History of Generic Drugs
2.3.2 The Hatch-Waxman Act: The Rise of Generics
2.4 Demonstrating Bioequivalence: A Major Factor in Approving Generics
2.5 Types of Generics - Authorised, Branded and Unbranded
2.6 Complex Generics
2.7 Classification of Generic Drugs Markets
2.8 Is Generic Substitution Bad News for Big Pharma Business?
2.8.1 The 'Ever greening' of Pharmaceutical Products
2.9 Regulation of Generic Drugs
2.9.1 Regulation in the US
2.9.1.1 Obtaining FDA Approval: NDAs and ANDAs
2.9.1.2 The Hatch-Waxman Act Title I: Promotion of Generic Drugs
2.9.1.3 The Hatch-Waxman Act Title II: Incentives for the Branded Industry
2.9.1.4 How Has the Hatch-Waxman Act Impacted upon the US Pharmaceutical Market?
2.9.1.5 How the Timing of Market Entry Influences Product Success
2.9.2 Regulation in Europe
2.9.2.1 EU Marketing Approval Procedures
2.9.2.2 The 8+2+1 Rule: EU Data Exclusivity
2.9.2.3 Supplementary Protection Certificates
2.9.2.4 Variation in Drug Development Regulations between European Countries
2.9.2.5 The Move towards the Harmonisation of Standards
2.9.2.6 The Impact of Europe’s Unitary Patent System on Generic Drugs:
2.9.2.7 In or Out: Unitary Patent Strategy for European Generic Drug Manufacturing
2.9.3 Regulation in Japan
2.9.4 Regulation in China
2.10 Compulsory Licensing
2.11 Market Definition and Scope of This Report
2.11.1 Market Sizing and Revenue Reporting
2.11.2 Currency Exchange Rates in This Report

3. Generic Drugs Market, 2017-2027
3.1 The Global Generic Drugs Market: Market Overview
3.1.1 Segmenting the Global Generic Drugs Market
3.2 The Rise of the Global Generic Drugs Market in 2016
3.3 Changes in the Regional Distribution of the Generic Drugs Market 2015-2016
3.4 The Global Generic Drugs Market: Sales Forecast 2017-2027
3.5 Generic Drugs: Regional Market Forecast 2017-2027
3.5.1 Changes in Generic Drug Regional Market Shares 2017-2027
3.6 Leading National Markets for Generic Drugs: Market Forecast 2017-2027
3.7 National Markets that will Drive Generic Drugs Growth
3.8 Changes in Market Shares by National Market, 2017-2027
3.9 Drivers and Restraints for the Global Generic Drugs Market 2017-2027

4. US Generic Drugs Market, 2017-2027
4.1 Generic Drugs in the US: Market Overview
4.1.1 The Effects of Generics on Healthcare Spending in the US
4.1.2 The Hatch-Waxman Act and Its Ongoing Effects
4.1.3 Consolidation in the Drug Development and Supply Chain Driving US Generics
4.2 US Historical Generic Penetration Rates
4.3 Leading Companies Operating within the US Generic Drugs Market
4.3.1 The Increasing Acceptance of Generics amongst Consumers
4.3.2 Affordable Care Act: Expanding Medicare Coverage
4.4 The US Generic Drugs Market: Drivers and Restraints 2017-2027
4.5 The US Generic Drugs Market Forecast: 2017-2027
4.6 The US Generic Drugs Market – Strategic Analysis
4.6.1 Will Biosimilars Dictate the Future of the US Generics Market?
4.6.2 The Backlog of ANDA Applications
4.6.3 The Generic Drug User Fee Amendments (GDUFA)
4.6.4 Shortages of Generic Drugs Will Restrain the Market
4.6.5 The Anti-Competitive ‘Pay for Delay’ Effect
4.7 US Generic Drugs Market: A Range of Factors Contributing to Growth

5. Leading European Generic Drugs Market, 2017-2027
5.1 European Generic Drugs: Market Overview
5.1.1 The EU5
5.1.2 Why Growth in Some Markets is Being Hindered?
5.1.3 Predominant Pricing Systems and Generic Penetration in European Markets
5.1.3.1 Lower Patient Co-Payments Drive for Generics
5.1.3.2 The Effects of Tendering for Generic Medicines
5.1.4 Will Europe Move towards Free-Pricing Systems?
5.1.5 Challenges in the European Regulatory Environment
5.1.6 Ending Anti-Competitive ‘Pay for Delay’ Tactics in Europe
5.1.7 FDA and EMA Joint Data Sharing and Inspections
5.2 EU5 Generic Drugs Market Forecast: 2017-2027
5.3 EU5 Market Share Breakdown 2017-2027
5.4 Germany: New Reforms to Medicinal Pricing May Impact Market Entry
5.4.1 German Generic Drugs Market: Generic Penetration by Volume, 2001-2016
5.4.2 German Generic Drugs Market: Generic Penetration by Value, 2001-2016
5.5 UK Generic Drugs Market: A Mature Market with Growth Potential
5.5.1 UK Generic Drugs Market: Sales Forecast 2017-2027
5.5.2 Cost Pressures and Demand-Side Policies Drive UK Generic Penetration
5.5.3 UK Generic Drugs Market: Generic Penetration by Volume, 2001-2016
5.5.4 UK Generic Drugs Market: Generic Penetration by Value, 2001-2016
5.5.5 Pharmacists as Enforcers of Generic Substitution
5.5.6 Pay Time for ‘Pay-For-Delay’
5.5.7 GSK: Widening the Gate to Accessible Medicines
5.6 French Generic Drugs Market: Healthcare Reforms Impacting on Market Growth
5.6.1 French Generic Drugs Market: Sales Forecast 2017-2027
5.6.2 French Generic Drugs Market: Generic Penetration by Volume, 2001-2016
5.6.3 French Generic Drugs Market: Generic Penetration by Value, 2001-2016
5.7 Italian Generic Drugs Market: Branded Generics Hindering Overall Growth
5.7.1 The Tightening of Italy’s Patent Legislations
5.7.2 The Italian Healthcare System – A Tale of Falling Budgets
5.7.3 Italian Generic Drugs Market: Sales Forecast: 2017-2027
5.7.4 Italian Generic Drugs market: Generic Penetration by Volume
5.7.5 Italian Generic Drugs Market: Generic Penetration by Value
5.8 Spanish Generic Drugs Market: Room for Growth
5.8.1 Cost-Containment Measures Helping to Boost Generic Drug Use
5.8.2 Spanish Generic Drugs Market: Sales Forecast 2017-2027
5.8.3 Spanish Generic Drugs Market: Generic Penetration by Volume, 2001-2016
5.8.4 Spanish Generic Drugs Market: Generic Penetration by Value, 2001-2016

6. Asia-Pacific Generic Drugs Market, 2017-2027
6.1 Generic Drugs in the Asia-Pacific Market: Market Overview
6.2 Chinese Generic Drugs Market: Domestic Companies Dominate the Market Landscape
6.2.1 The Major Drivers of Growth in the Chinese Generics Market
6.2.2 Chinese Generic Drugs Market: Sales Forecast 2017-2027
6.2.3 Compulsory Licensing of Generic Drugs
6.2.4 Expansion of Healthcare Coverage and Reimbursement
6.2.5 Chinese Generic Drugs Market: Generic Penetration by Volume, 2001–2016
6.2.6 Chinese Generic Drugs Market: Generic Penetration by Value, 2001-2016
6.2.7 The Impacts of Price Controls and the Anhui Model
6.3 Japanese Generic Drugs Market: High Barriers to Entry
6.3.1 Public Perception of Generics in Japan
6.3.2 Japanese Generic Drugs Market: Leading Companies
6.3.3 Japanese Generic Drugs Market: Sales Forecast 2017-2027
6.3.4 Japanese Generic Drugs Market: Generic Penetration by Volume, 2001–2016
6.3.5 Japanese Generic Drugs Market: Generic Penetration by Value, 2001-2016
6.3.6 Government Initiatives Driving Generic Penetration
6.3.7 Japanese Attitudes to Generic Drugs
6.4 Indian Generic Drugs Market: Regulatory Failures Hindering Sales Growth
6.4.1 Leading Companies in the Indian Generic Drugs Market
6.4.2 Indian Generic Drugs Market: Sales Forecast 2017-2027
6.4.3 The Reforms to India’s Drug Prices Control Order and Its Likely Effects on Generic Drugs Revenues
6.4.4 Expansion of the National Healthcare Coverage Increases the Need for Generics
6.4.5 Has Recent Manufacturing Quality Failures Dented India’s Generics Growth?

7. Emerging Generic Drugs Market, 2017-2027
7.1 Generic Drugs in the Emerging Market: Market Overview
7.1.1 Emerging Economies: Improving Logistics and Better Infrastructure Catalysing Generics Growth
7.2 Brazil Generic Drugs Market
7.2.1 Brazilian Generic Drugs Market: Sales Forecast 2017-2027
7.2.2 Generics to Facilitate Low-Income Earner’s Access to Medicines
7.2.3 Foreign Generic Drug Manufacturers Entering the Brazilian Market
7.3 Russian Generic Drugs Market: Improving IP Protection to Aid Market Growth
7.3.1 Historical Trends in Russia’s Pharmaceutical Production and Distribution
7.3.2 The Pharma2020 Strategy - Healthcare and Industry Reform
7.3.3 Self-Medication in Russia and the Integral Role of Pharmacies
7.3.4 Russian Generic Drugs Market: Sales Forecast 2017-2027
7.4 Mexican Generic Drugs Market: Boost by Investment from the Government
7.4.1 Government Programmes to Vitalise Generic Penetration in Mexico
7.4.2 Regulatory Changes and the Inception of COFEPRIS
7.4.3 Mexican Generic Drugs Market: Sales Forecast 2017-2027
7.5 South Korean Generic Drugs Market: Expected to Continue Its Trend of Growth
7.5.1 Pharmaceutical Price Controls and Measures Being Implemented in South Korea
7.5.1.1 KORUS FTA: The Free Trade Agreement between South Korea and the US
7.5.1.2 The Free Trade Agreement between Korea and the European Union
7.5.2 South Korean Generic Drugs Market: Sales Forecast 2017-2027
7.6 Turkish Generic Drugs Market: Price Cuts May Impact the First Half of the Forecast Period
7.6.1 Cost Cutting Measures and their Effects on Turkish Generics
7.6.2 Will Turkey Become a Production Base for High Technology Products?
7.6.3 Turkish Generic Drugs Market: Sales Forecast 2017-2027
7.6.4 Regulatory Guidelines for Generic Drugs in Turkey
7.6.5 How Effective has Turkey’s Health Transformation Programme Been?

8. Leading Companies in The Generic Drugs Market, 2017-2027
8.1 Generic Drugs: Continuous Expansion to Rival
8.1.1 The Leading Companies in the Global Generics Market
8.2 Teva
8.2.1 Teva: Historical Financial and Performance Analysis, 2011-2015
8.2.2 Teva Generic Drugs Sales Forecast 2017-2027
8.2.3 Teva and Allergan Spin-Off Generic Drug Deal
8.2.4 Allergan: Historical Financial and Performance Analysis, 2011-2015
8.2.5 Allergan: Developments in Generic Drug Segment Prior Mega-Deal
8.2.5.1 Exit from the Chinese Generics Market
8.2.5.2 Further Entry into the Japanese Generics Market
8.2.6 Teva: Generic Drugs Portfolio Analysis, 2017
8.2.6.1 High-Value Generics to Drive Teva’s Generics Growth?
8.2.6.2 The Shift Towards Innovation
8.2.6.3 Glatiramer Acetate Injection Leads Teva’s Moving Focus
8.2.6.4 The Threat of Generic Erosion to Teva’s Products
8.2.7 Teva: What Future Moves Could We Expect?
8.3 Novartis
8.3.1 Novartis: Historical Financial and Performance Analysis, 2011-2015
8.3.2 Novartis Generic Drugs Sales Forecast 2017-2027
8.3.3 Novartis Generic Drugs Portfolio Analysis, 2017
8.3.3.1 Emphasis on Difficult-to-Manufacture Products
8.3.4 What Does the Future Hold for Novartis’ Generic Drugs Business?
8.4 Mylan
8.4.1 Mylan: Historical Financial and Performance Analysis, 2011-2015  
8.4.2 Mylan Generic Drugs Sales Forecast 2017-2027
8.4.3 Mylan: Recent Developments
8.4.3.1 Acquisition of Abbott’s Generic Business
8.4.3.2 Mylan’s Growth in Manufacturing Capacity
8.4.3.3 Mylan Acquires Rights to GSK’s Advair, Diskus and Seretide
8.4.3.4 The Race to Market Capoxone Generics
8.4.3.5 Strategic Acquisition of Agila Expands Mylan’s Injectables Business
8.4.4 Mylan’s Collaborative Efforts
8.4.4.1 Biosimilar Collaboration with India’s Biocon
8.4.4.2 Biosimialr Collaborations with Momenta
8.4.5 What Does the Future Hold for Mylan’s Generic Drugs Business?
8.5 Pfizer
8.5.1 Pfizer: Historical Financial and Performance Analysis, 2011-2015
8.5.2 Pfizer’s Restructuring Strategy
8.5.3 Pfizer’s Done Deal with Hospira
8.5.4 Pfizer Generic Drugs Sales Forecast 2017-2027
8.5.5 Hospira: A Brief Overview of Operations
8.5.6 Hospira: Historical Financial and Performance Analysis 2011-2015
8.5.7 Hospira: Recent Developments
8.5.7.1 Hospira’s Expansion through Strategic Acquisitions Hospira: Manufacturing Concerns and Remediation Efforts
8.5.8 Future Prospects for Pfizer’s Generic Business
8.5.8.1 The Pfizer-Allergan Deal Falls Through
8.5.8.2 Activities of Allergan (Actavis) Prior to Mega-Merger
8.5.8.3 Actavis’ Work on Biosimilars
8.6 Abbott
8.6.1 Abbott: Historical Financial and Performance Analysis, 2011-2015
8.6.2 Abbott Generic Drugs Sales Forecast 2017-2027
8.6.3 Abbott: Recent Developments
8.6.3.1 Abbott after the Spin-Off of AbbVie – The Established Products Business Segment
8.6.3.2 Acquisition of Solvay Pharmaceutcials and Piramal Healthcare Solutions
8.6.3.3 Acquisition of CFR Pharmaceuticals Opens New Markets
8.6.4 What Does the Future Hold for Abbott’s Generic Drugs Business?
8.7 Sun Pharma
8.7.1 Sun Pharma’s Business Areas
8.7.2 Sun Pharma: Historical Financial and Performance Analysis, 2011-2015
8.7.3 Sun Pharma Generic Drugs Sales Forecast 2017-2027
8.7.4 Sun Pharma-Ranbaxy Acquisition
8.8 Aspen
8.8.1 Aspen: Historical Financial and Performance Analysis, 2011-2015
8.8.2 Aspen Generic Sales Forecast 2017-2027
8.8.3 Aspen: Recent Developments
8.8.3.1 Aspen Acquires Merck MSD’s Dutch API Plant
8.8.3.2 Acquisition of GSK’s Anti-Thrombosis Brands
8.8.4 Future Outlook for Aspen’s Generic Business
8.9 Fresenius Kabi
8.9.1 Fresenius Kabi: Historical Financial and Performance Analysis, 2011-2015
8.9.2 Fresenius Kabi Generic Drugs Sales Forecast 2017-2027
8.9.3 InnoPharma Licensing Deal Bolsters Portfolio Grown Via Past Acquisitions
8.9.4 Fresenius Kabi’s Joint Venture with PT Soho Global Health
8.9.5 Future Prospects for Fresenius Kabi’s Generics Business
8.10 Sanofi
8.10.1 Sanofi: Historical Financial and Performance Analysis, 2011-2015
8.10.2 Sanofi Generic Sales Forecast 2017-2027
8.10.3 Sanofi’s Response to Lantus Competition
8.10.3.1 Emerging Market Acquisitions
8.10.4 Sanofi’s Strategies to Develop Generic Sales

9. Qualitative Analysis of the Generic Drugs Market, 2017-2027
9.1 Market Factors Influencing the Global Generic Drugs Market
9.2 SWOT Analysis of the Global Generic Drugs Market, 2017-2027
9.2.1 Strengths
9.2.1.1 Improving Clarity around Regulatory Processes
9.2.1.2 The Continuous Government Support for Generic Manufacturers – Precursors for Innovation
9.2.1.3 Higher Pace of Growth Compared with Innovative Pharma
9.2.1.4 Globalisation and Its Impact on Manufacturing Capabilities
9.2.2 Weaknesses
9.2.2.1 Safety and Quality Concerns in the Manufacturing Process
9.2.2.2 The Non-Uniformity of Excipients
9.2.2.3 The Uncertainty around Patent Extensions and Exclusivities
9.2.2.4 Sceptical Physicians and the Negative Consumer Perception of Generics
9.2.2.5 Inefficiencies in Certain Regulatory Approval Processes
9.2.3 Opportunities
9.2.3.1 Higher Value Biosimilars and Branded Generics
9.2.3.2 Patent Expiries Creating Opportunities
9.2.3.3 Changing Scio-Economic Conditions Impacting Generic Drugs Demand
9.2.3.4 Emerging Markets – Expected to Drive Generics Volume Growth over Time
9.2.4 Threats
9.2.4.1 Government Cost-Cutting Initiatives Impacting on Generic Drugs Prices
9.2.4.2 The Complexity Surrounding Patents and Patents Expiries
9.2.4.3 Pharmacies and Healthcare Payer Consolidations
9.2.4.4 Possible Impacts of a Declining Pool
9.3 Porter’s Five Force Analysis of the Global Generic Drugs Market, 2017-2027
9.3.1 Power of Buyers: Medium
9.3.2 Power of Suppliers: Low
9.3.3 Rivalry among Competitors: High
9.3.4 Threat of New Entrants: High
9.3.5 Threat of Substitutes: Low

10. Conclusions
10.1 Overview of Current Market Conditions and Market Forecast, 2017-2027
10.2 Generic Drugs as a Strategic Tool in Healthcare
10.3 Major Drivers of Growth for Generic Drugs, 2017-2027
10.4 The Regulatory Landscape for Generic Drugs
10.5 Leading Generic Drug Manufacturers
10.6 Future Outlook for the Leading Regions within the Global Generic Drugs Market, 2017-2027
10.7 Generic Penetration by Volume in Leading National Markets
10.8 What Does the Future Hold for the Global Generic Drugs Market?

11. Glossary

Appendix
Visiongain’s Bespoke Research Service
Some Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Report Evaluation Form

List of Tables
Table 1.1 Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by National Markets, 2015-2027 (Redacted Data)
Table 2.1 Types of Drug Names, 2017
Table 2.2 Currency Exchange Rates, 2016
Table 3.1 The Global Generic Drugs Market Size: Revenue ($bn) and Market Share (%) by Leading National Markets, 2015 and 2016
Table 3.2 The Global Generic Drugs Market Size: Revenue ($bn) and Market Share (%) by Region, 2015 and 2016
Table 3.3 The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 3.4 The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Region, 2015-2027
Table 3.5 The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2015, 2021, and 2027
Table 3.6 The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by National Market, 2015-2027
Table 3.6 (cont’d) The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by National Market, 2015-2027
Table 3.7 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2015-2021, 2021-2027, 2015-2027
Table 3.8 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2015, 2021, and 2027
Table 3.9 Global Generic Drugs Market Drivers and Restraints, 2015-2027
Table 4.1 US Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%) 2005-2016
Table 4.2 US Generic Drugs Market Drivers and Restraints, 2017-2027
Table 4.3 US Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 5.1 The EU5 Generic Drugs Market: Revenue ($bn) and Market Share (%) by Country, 2015 and 2016
Table 5.2 EU5 Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 5.3 The EU5 Generic Drugs Market: Market Share (%) by Country, 2015, 2021, 2027
Table 5.4 The German Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 5.5 German Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
Table 5.6 German Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical Sales (%) and AGR (%), 2001-2016
Table 5.7 The UK Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 5.8 UK Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
Table 5.9 UK Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2001-2016
Table 5.10 The French Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 5.11 French Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
Table 5.12 French Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical Sales (%) and AGR (%), 2001-2016
Table 5.13 The Italian Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 5.14 Italian Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2017
Table 5.15 Italian Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical Sales (%) and AGR (%), 2001-2016
Table 5.16 The Spanish Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and (CAGR%), 2015-2027
Table 5.17 Spanish Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
Table 5.18 Spanish Generic Drugs Market: Generic Penetration of Total Pharmaceutical Sales (%) and AGR (%), 2001-2016
Table 6.1 The Chinese Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 6.2 Chinese Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
Table 6.3 Chinese Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical Sale (%) and AGR (%), 2001-2016
Table 6.4 The Japanese Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 6.5 Japanese Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
Table 6.6 Japanese Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical Sales (%) and AGR (%), 2001-2016
Table 6.7 The Indian Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 6.8 Leading Drug Types in Indian Pharmaceutical Market: Revenue ($bn) and Market Share (%), 2016, 2021 & 2027
Table 7.1 The Brazilian Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 7.2 The Russian Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 7.3 The Mexican Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 7.4 The South Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 7.5 The Turkish Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 8.1 Top Generic Drugs Manufacturers: Total Revenue ($bn), Generic Drugs Revenue ($bn) and Generic Share of Revenue (%), 2015 and 2016
Table 8.2 Teva: Company Overview, 2015-2016
Table 8.3 Teva: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Table 8.4 Teva Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 8.5 Allergan: Company Overview 2015-2016
Table 8.6 Allergan: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Table 8.7 Novartis: Overview, 2015-2016
Table 8.8 Novartis: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Table 8.9 Novartis Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 8.10 Mylan: Company Overview, 2015-2016
Table 8.11 Mylan: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Table 8.12 Mylan: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 8.13 Pfizer: Company Overview, 2015-2016
Table 8.14 Pfizer: Historical ‘Established Products’ Drugs Sales ($bn) and AGR (%), 2011-2015
Table 8.15 Pfizer: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 8.16 Hospira: Company Overview, 2014-2015
Table 8.17 Hospira: Historical Specialty Injectables Sales ($bn) and AGR (%), 2011-2015
Table 8.18 Allergan: Company Overview, 2015-2016
Table 8.19 Abbott: Company Overview, 2015-2016
Table 8.20 Abbott: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Table 8.21 Abbott: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 8.22 Sun Pharmaceuticals: Company Overview, 2015-2016
Table 8.23 Sun Pharma: Historical Generic Drugs Sales ($bn), 2011-2015
Table 8.24 Sun Pharma Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 8.25 Aspen: Company Overview, 2015-2016
Table 8.26 Aspen: Historical Revenue ($bn) and AGR (%), 2011-2015
Table 8.27 Aspen Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 8.28 Fresenius Kabi: Company Overview, 2015-2016
Table 8.29 Fresenius Kabi: Historical Generic Drugs Sales ($bn), 2011-2015
Table 8.30 Fresenius Kabi: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 8.31 Sanofi: Company Overview, 2015-2016
Table 8.32 Sanofi: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Table 8.33 Sanofi Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2027
Table 9.1 SWOT Analysis of the Generic Drugs Market, 2017-2027
Table 9.2 World 65+ Population Forecast: Size (m), AGR (%) and CAGR (%), 2015-2027
Table 10.1 Global Generic Drugs Market Forecast: Revenue ($bn) and CAGR (%), 2015, 2021 and 2027
Table 10.2 Top Generic Drug Manufacturers: Generic Drugs Revenue ($bn) and Market Share (%), 2016
Table 10.3 Global Generic Drugs Market Forecast: Revenue ($bn) by National Markets, 2015, 2021 and 2027
Table 10.4 US, EU5 and Japan Generic Drugs Market Forecast: Revenue ($bn), 2015-2027
Table 10.5 BRIC Generic Drugs Market Forecast: Revenue ($bn), 2015-2027
Table 10.6 Mexico, South Korea, and Turkey Generic Drugs Market Forecast: Revenue ($bn), 2015-2027
Table 10.7 Generic Drug Penetration by Volume in Leading National Markets (%), 2016

List of Figures
Figure 1.1 Global Generic Drugs Market Segmentation
Figure 2.1 EU Data Exclusivity for Generics: Possible Scenarios, 2016
Figure 3.1 The Global Generic Drugs Market Size: Revenue ($bn) by Leading National Markets, 2015
Figure 3.2 The Global Generic Drugs Market Size: Revenue ($bn) by Leading National Markets, 2016
Figure 3.3 The Global Generic Drugs Market Size: Revenue ($bn) by Region, 2015
Figure 3.4 The Global Generic Drugs Market Size: Revenue ($bn) by Region, 2016
Figure 3.5 Global Generic Drugs Market Forecast: ($bn) and AGR (%), 2015-2027
Figure 3.6 The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2015
Figure 3.7 The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2021
Figure 3.8 The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2027
Figure 3.9 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2015-2021
Figure 3.10 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2021-2027
Figure 3.11 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2015-2027
Figure 3.12 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2015
Figure 3.13 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2021
Figure 3.14 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2027
Figure 4.1 US Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%) 2005-2016
Figure 4.2 US Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2015-2027
Figure 5.1 The EU5 Generic Drugs Market: Revenues ($bn) by Country, 2015
Figure 5.2 The EU5 Generic Drugs Market: Revenues ($bn) by Country, 2016
Figure 5.3 Germany, France, UK, Italy, and Spain Generic Drugs Market Forecast: Revenue ($bn), 2015-2027
Figure 5.4 The EU5 Generic Drugs Market: Market Share (%) by Country, 2015
Figure 5.5 The EU5 Generic Drugs Market: Market Share (%) by Country, 2021
Figure 5.6 The EU5 Generic Drugs Market: Market Share (%) by Country, 2027
Figure 5.7 The German Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 5.8 German Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
Figure 5.9 German Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2001-2016
Figure 5.10 The UK Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 5.11 UK Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
Figure 5.12 UK Generic Drugs Market: Generic Penetration by Value (%) and AGR (%), 2001-2016
Figure 5.13 The French Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 5.14 French Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
Figure 5.15 French Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical sales (%) and AGR (%), 2001-2016
Figure 5.16 The Italian Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 5.17 Italian Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
Figure 5.18 Italian Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical Sales (%) and AGR (%), 2001-2016
Figure 5.19 The Spanish Generic Drugs Market Forecast: Revenue ($bn), AGR (%) , 2015-2027
Figure 5.20 Spanish Generic Drugs Market: Generic Penetration by Volume of Prescriptions (%) and AGR (%), 2001-2016
Figure 5.21 Spanish Generic Drugs Market: Generic Penetration by Proportion of Pharmaceutical Sales (%) and AGR (%), 2001-2016
Figure 6.1 China, Japan and India Generic Drugs Market Forecast: Revenue ($bn), 2015-2027
Figure 6.2 The Chinese Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 6.3 Chinese Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%), 2001-2016
Figure 6.4 Chinese Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical Sale (%) and AGR (%), 2001-2016
Figure 6.5 The Japanese Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2015-2027
Figure 6.6 Japanese Generic Drugs Market: Generic Penetration by Volume (%) and AGR (%) 2001-2016
Figure 6.7 Japanese Generic Drugs Market: Generic Penetration by Proportion of Total Pharmaceutical Sales (%) and AGR (%) 2001-2016
Figure 6.8 The Indian Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2015-2027
Figure 6.9 Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2016
Figure 6.10 Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2021
Figure 6.11 Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2027
Figure 7.1 Brazil, Russia, Mexico, South Korea and Turkey Generic Drugs Market Forecast: Revenue ($bn), 2015-2027
Figure 7.2 The Brazilian Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2015-2027
Figure 7.3 The Russian Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 7.4 The Mexican Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 7.5 The South Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2015-2027
Figure 7.6 The Turkish Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 8.1 Top Generic Drugs Manufacturers: Generic Drugs Revenue ($bn), 2015
Figure 8.2 Top Generic Drugs Manufacturers: Generic Drugs Revenue ($bn), 2016
Figure 8.3 Teva: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Figure 8.4 Teva Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 8.5 Allergan: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Figure 8.6 Novartis: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Figure 8.7 Novartis Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 8.8 Mylan: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Figure 8.9 Mylan: Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 8.10 Pfizer: Historical ‘Established Products’ Drugs Sales ($bn) and AGR (%), 2011-2015
Figure 8.11 Pfizer Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 8.12 Hospira: Historical Specialty Injectables Sales ($bn) and AGR (%), 2011-2015
Figure 8.13 Abbott: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Figure 8.14 Abbott Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 8.15 Sun Pharma: Historical Generic Drugs Sales (Rs.bn) and AGR (%), 2011-2015
Figure 8.16 Sun Pharma: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Figure 8.17 Sun Pharma Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 8.18 Aspen: Historical Revenue ($bn) and AGR (%), 2011-2015
Figure 8.19 Aspen: Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 8.20 Fresenius Kabi: Historical Generic Drugs Sales (€bn) and AGR (%), 2011-2015
Figure 8.21 Fresenius Kabi: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Figure 8.22 Fresenius Kabi Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 8.23 Sanofi: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
Figure 8.24 Sanofi Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2015-2027
Figure 9.1 World 65+ Population Forecast: Size (m) and AGR (%), 2015-2027
Figure 9.2 Porter’s Five Force Analysis of the Global Generic Drugs Market, 2017
Figure 10.1 Global Generic Drugs Market Forecast: Revenue ($bn), 2015, 2021 and 2027
Figure 10.2 US, EU5 and Japan Generic Drugs Market Forecast: Revenue ($bn), 2015-2027
Figure 10.3 BRIC Generic Drugs Market Forecast: ($bn), 2015-2027
Figure 10.4 Mexico, South Korea, and Turkey Generic Drugs Market Forecast: Revenue ($bn), 2015-2027
Figure 10.5 Generic Drug Penetration by Volume in Leading National Markets (%), 2016